<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0201242</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-34120</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>Granulomas</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>Granulomas</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>Granulomas</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Bacterial diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Tropical diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Computed axial tomography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Computed axial tomography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Computed axial tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Computed axial tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Radiology and imaging</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Computed axial tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Professions</subject><subj-group><subject>Medical personnel</subject><subj-group><subject>Medical doctors</subject><subj-group><subject>Physicians</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Health care</subject><subj-group><subject>Health care providers</subject><subj-group><subject>Medical doctors</subject><subj-group><subject>Physicians</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Lung and intrathoracic tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Radiology and imaging</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Tomography</subject><subj-group><subject>Positron emission tomography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject><subj-group><subject>Surgical oncology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical medicine</subject><subj-group><subject>Clinical oncology</subject><subj-group><subject>Surgical oncology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Clinical oncology</subject><subj-group><subject>Surgical oncology</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Comparison of four models predicting the malignancy of pulmonary nodules: A single-center study of Korean adults</article-title>
<alt-title alt-title-type="running-head">Comparison of malignancy prediction models</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Yang</surname>
<given-names>Bumhee</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Jhun</surname>
<given-names>Byung Woo</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Shin</surname>
<given-names>Sun Hye</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Jeong</surname>
<given-names>Byeong-Ho</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Um</surname>
<given-names>Sang-Won</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zo</surname>
<given-names>Jae Il</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lee</surname>
<given-names>Ho Yun</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sohn</surname>
<given-names>Insoek</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Hojoong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kwon</surname>
<given-names>O. Jung</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1642-8111</contrib-id>
<name name-style="western">
<surname>Lee</surname>
<given-names>Kyungjong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Statistics and Data Center, Samsung Medical Center, Seoul, Korea</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Ghavami</surname>
<given-names>Saeid</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Manitoba, CANADA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">kj2011.lee@samsung.com</email>, <email xlink:type="simple">kj2011.lee@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>7</issue>
<elocation-id>e0201242</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Yang et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0201242"/>
<abstract>
<sec id="sec001">
<title>Objective</title>
<p>Four commonly used clinical models for predicting the probability of malignancy in pulmonary nodules were compared. While three of the models (Mayo Clinic, Veterans Association [VA], and Brock University) are based on clinical and computed tomography (CT) characteristics, one model (Herder) additionally includes the <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake value among the positron emission tomography (PET) characteristics. This study aimed to compare the predictive power of these four models in the context of a population drawn from a single center in an endemic area for tuberculosis in Korea.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>A retrospective analysis of 242 pathologically confirmed nodules (4–30 mm in diameter) in 242 patients from January 2015 to December 2015 was performed. The area under the receiver operating characteristic curve (AUC) was used to assess the predictive performance with respect to malignancy.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Of 242 nodules, 187 (77.2%) were malignant and 55 (22.8%) were benign, with tuberculosis granuloma being the most common type of benign nodule (23/55). PET was performed for 227 nodules (93.8%). The Mayo, VA, and Brock models showed similar predictive performance for malignant nodules (AUC: 0.6145, 0.6042 and 0.6820, respectively). The performance of the Herder model (AUC: 0.5567) was not significantly different from that of the Mayo (vs. Herder, p <italic>=</italic> 0.576) or VA models (vs. Herder, p <italic>=</italic> 0.999), and there were no differences among the three models in determining the probability of malignancy of pulmonary nodules. However, compared with the Brock model, the Herder model showed a significantly lower ability to predict malignancy (adjusted p <italic>=</italic> 0.0132).</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>In our study, the Herder model including the <sup>18</sup>FDG uptake value did not perform better than the other models in predicting malignant nodules, suggesting the limited utility of adding PET/CT data to models predicting malignancy in populations within endemic areas for benign inflammatory nodules, such as tuberculosis.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The authors received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<page-count count="10"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Pulmonary nodules are being detected with increasing frequency because of the increased use of chest computed tomography (CT) [<xref ref-type="bibr" rid="pone.0201242.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0201242.ref002">2</xref>]. Recent low-dose chest CT screening trials showed a beneficial effect on survival for individuals at increased risk of lung cancer [<xref ref-type="bibr" rid="pone.0201242.ref003">3</xref>–<xref ref-type="bibr" rid="pone.0201242.ref006">6</xref>]. However, the management of pulmonary nodules incidentally detected on CT is a pressing clinical concern because accurately predicting malignant nodules is not straightforward.</p>
<p>Recently, several prediction models using clinical and radiological values have been developed that can help physicians to distinguish between benign and malignant nodules [<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>]. The classical prediction models (Mayo Clinic [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>], Veterans Association (VA) [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>], and Brock University [<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>]) only include clinical values and radiological characteristics on CT, while a fourth model proposed by Herder et al. [<xref ref-type="bibr" rid="pone.0201242.ref011">11</xref>] additionally includes the <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake value in positron emission tomography/computed tomography (PET/CT). The Mayo model [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>] that was developed in 1997 includes older age, smoking history, cancer history, nodule diameter, location of nodule (especially the upper lobe), and spiculation. The VA model [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>] developed in 2007 includes patient age, smoking history, and nodule diameter. The Brock model [<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>] developed in 2013 includes age, family history of lung cancer, sex, nodule size, emphysema, nodule count, location of the nodule in the upper lobe, spiculation and part-solid nodule. The Herder model was developed in 2005 at a single center, by analyzing data from 106 patients who underwent <sup>18</sup>FDG-PET, to allow optimization of the prior Mayo model [<xref ref-type="bibr" rid="pone.0201242.ref011">11</xref>] and has already been reported to be a more useful model for predicting malignancy versus the other models [<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0201242.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0201242.ref013">13</xref>].</p>
<p>However, because <sup>18</sup>FDG is a marker of glucose metabolism and is not a specific tracer for malignancy, inflammatory lung lesions, such as tuberculous granuloma and parasite infection, can mimic malignancy and yield false-positive results on PET/CT scans. Moreover, given that the prevalence of tuberculosis among the Korean population in endemic areas is in the intermediate range (70–90/100,000 persons/year) [<xref ref-type="bibr" rid="pone.0201242.ref014">14</xref>], various malignancy prediction models for pulmonary nodules should be considered in Korean adults. Therefore, in this study, we aimed to compare the predictive power of these four models in patients with biopsy-proven pulmonary lung nodules at a single center in Korea.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Study population</title>
<p>We retrospectively reviewed the medical records of 429 consecutive adult patients, with pulmonary nodules 4–30 mm in size, who underwent histopathologic confirmation at the Samsung Medical Center (a 1,979-bed referral hospital in Seoul, South Korea) between January 1, 2015 and December 31, 2015. Of these patients, 20 with more than five nodules, 70 with pure ground glass nodules, and 97 with lymphadenopathy or suspected metastatic disease on chest CT were excluded. As a result, 242 patients were included in the study, and 242 nodules that were confirmed by surgical resection or percutaneous needle aspiration were analyzed; of these, 187 (77.2%) were malignant, and the remaining 55 (22.8%) were benign (<xref ref-type="fig" rid="pone.0201242.g001">Fig 1</xref>). PET/CT was performed in 227 patients (93.8%).</p>
<fig id="pone.0201242.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Study patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.g001" xlink:type="simple"/>
</fig>
<p>The Institutional Review Board of Samsung Medical Center approved this study and permitted the review and publication of patient records (IRB No.2017-04-002). The requirement for informed consent of individual patients was waived given the retrospective nature of the study.</p>
</sec>
<sec id="sec008">
<title>Model for predicting malignancy</title>
<p>In this study, the probability of malignancy of pulmonary nodules was calculated using four models (Mayo [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>], VA [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>], Brock [<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>], and Herder [<xref ref-type="bibr" rid="pone.0201242.ref002">2</xref>]). Three models (Mayo [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>], VA [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>], and Brock [<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>]) are based on clinical values and CT findings. The fourth model (Herder [<xref ref-type="bibr" rid="pone.0201242.ref002">2</xref>]) adds characteristics of PET/CT in the Mayo Clinic [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>] models. In accordance with Al-Ameri et al. [<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>], the nodules were classified according to their <sup>18</sup>FDG avidity (standardized uptake value [SUV] or maximum standardized uptake value [SUV<sub>max</sub>]), as follows: faint uptake, SUV<sub>max</sub> ≤ 2.5; moderate uptake, SUV<sub>max</sub> 2.6–10.0; and intense uptake, SUV<sub>max</sub> &gt; 10.0 [<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>].</p>
</sec>
<sec id="sec009">
<title>Statistical analysis</title>
<p>The data are reported as numbers (%) for categorical variables and as medians (interquartile range, IQR) for continuous variables. We compared categorical variables using chi-squared test or Fisher’s exact test, and continuous variables using the Mann–Whitney <italic>U</italic> test. All tests were two-sided, and a P-value &lt; 0.05 was deemed to indicate statistical significance. A receiver operating characteristic (ROC) curve was constructed, and the area under the ROC curve (AUC) was calculated. To compare the AUC values between two models, the nonparametric approach of DeLong et al. [<xref ref-type="bibr" rid="pone.0201242.ref015">15</xref>] was used, and Bonferroni correction was applied to adjust for multiple comparisons. All statistical analyses were performed using SPSS (ver. 23.0; IBM Corp., Armonk, NY, USA) and R software (ver. 3.0.3; R Development Core Team, Vienna, Austria).</p>
</sec>
</sec>
<sec id="sec010" sec-type="results">
<title>Results</title>
<sec id="sec011">
<title>Baseline characteristics of the study patients and nodules</title>
<p>The baseline characteristics of the study patients and nodules are summarized in <xref ref-type="table" rid="pone.0201242.t001">Table 1</xref>. The median age of the 242 patients was 61.0 years (IQR: 54.0–67.0 years); 112 (46%) patients were male and 148 (61%) patients were never smokers. The mean number of nodules was 1.4 for benign nodules and 1.5 for malignant nodules.</p>
<table-wrap id="pone.0201242.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.t001</object-id>
<label>Table 1</label> <caption><title>Baseline characteristics of the study patients and nodules.</title></caption>
<alternatives>
<graphic id="pone.0201242.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">Clinical characteristics</th>
<th align="center">Total (N = 242, 100%)<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></th>
<th align="center">Benign (n = 55, 23%)</th>
<th align="center">Malignant<break/>(n = 187, 77%)</th>
<th align="center">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">Age, years</td>
<td align="center">61.0 (54.0–67.0)</td>
<td align="center">57.0 (50.3–65.0)</td>
<td align="center">62.0 (55.0–68.0)</td>
<td align="center">0.316</td>
</tr>
<tr>
<td align="justify">Sex, male</td>
<td align="center">112 (46)</td>
<td align="center">23 (42)</td>
<td align="center">89 (48)</td>
<td align="center">0.746</td>
</tr>
<tr>
<td align="justify">Never smoker</td>
<td align="center">148 (61)</td>
<td align="center">39 (71)</td>
<td align="center">109 (58)</td>
<td align="center">0.521</td>
</tr>
<tr>
<td align="justify">Comorbidities</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="justify">    Diabetes mellitus</td>
<td align="center">34 (14)</td>
<td align="center">11 (20)</td>
<td align="center">23 (12)</td>
<td align="center">0.138</td>
</tr>
<tr>
<td align="justify">    Hypertension</td>
<td align="center">59 (24)</td>
<td align="center">15 (27)</td>
<td align="center">44 (24)</td>
<td align="center">0.601</td>
</tr>
<tr>
<td align="justify">    Emphysema</td>
<td align="center">21 (9)</td>
<td align="center">2 (4)</td>
<td align="center">19 (10)</td>
<td align="center">0.261</td>
</tr>
<tr>
<td align="justify">    Tuberculosis history</td>
<td align="center">22 (9)</td>
<td align="center">6 (11)</td>
<td align="center">16 (9)</td>
<td align="center">0.791</td>
</tr>
<tr>
<td align="justify">    Idiopathic pulmonary fibrosis</td>
<td align="center">4 (2)</td>
<td align="center">1 (2)</td>
<td align="center">3 (2)</td>
<td align="center">0.999</td>
</tr>
<tr>
<td align="justify">Number of nodule</td>
<td align="center">1.5</td>
<td align="center">1.4</td>
<td align="center">1.5</td>
<td align="center">0.164</td>
</tr>
<tr>
<td align="justify">Nodule characteristics</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="justify">    Nodule size</td>
<td align="center">20.0 (15.0–25.0)</td>
<td align="center">19.0 (15.0–28.0)</td>
<td align="center">20.0 (15.0–24.0)</td>
<td align="center">0.702</td>
</tr>
<tr>
<td align="justify">    Part solid nodule</td>
<td align="center">121 (50)</td>
<td align="center">12 (22)</td>
<td align="center">109 (58)</td>
<td align="center">&lt; 0.001</td>
</tr>
<tr>
<td align="justify">    Spiculation</td>
<td align="center">32 (13)</td>
<td align="center">2 (4)</td>
<td align="center">30 (16)</td>
<td align="center">0.024</td>
</tr>
<tr>
<td align="justify">SUV<sub>max</sub><xref ref-type="table-fn" rid="t001fn003"><sup>b</sup></xref></td>
<td align="center">2.6 (1.4–4.4)</td>
<td align="center">3.1 (1.6–3.7)</td>
<td align="center">2.6 (1.4–4.8)</td>
<td align="center">0.165</td>
</tr>
<tr>
<td align="justify">    Faint</td>
<td align="center">114 (46)</td>
<td align="center">24 (44)</td>
<td align="center">90 (48)</td>
<td align="center"/>
</tr>
<tr>
<td align="justify">    Moderate</td>
<td align="center">93 (38)</td>
<td align="center">22 (40)</td>
<td align="center">71 (38)</td>
<td align="center"/>
</tr>
<tr>
<td align="justify">    Intense</td>
<td align="center">20 (8)</td>
<td align="center">2 (4)</td>
<td align="center">18 (10)</td>
<td align="center"/>
</tr>
<tr>
<td align="justify">Previous extra-thoracic cancer</td>
<td align="center">19 (8)</td>
<td align="center">4 (7)</td>
<td align="center">15 (8)</td>
<td align="center">0.999</td>
</tr>
<tr>
<td align="justify">Family history of lung cancer</td>
<td align="center">34 (14)</td>
<td align="center">5 (10)</td>
<td align="center">29 (16)</td>
<td align="center">0.275</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>SUV, standardized uptake value.</p></fn>
<fn id="t001fn002"><p><sup>a</sup>The data are presented as numbers (%) or medians (interquartile range).</p></fn>
<fn id="t001fn003"><p><sup>b</sup>Fifteen patients, including seven patients in the benign nodule group and eight in the malignant group, lacked SUV<sub>max</sub> values because they did not undergo PET/CT.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The mean size of the 242 nodules was 20.0 mm (IQR: 15.0–25.0 mm); 121 (50%) had part-solid nodules, 32 (13%) showed characteristics of spiculation, and the mean SUV was 2.6 (IQR: 1.4–4.4). In total, 114 (46%) nodules showed faint uptake, 93 (38%) showed moderate uptake, and 20 (8%) showed intense uptake. Of the 55 benign nodules, 24 (44%) showed faint uptake, 22 (40%) showed moderate uptake, and 2 (4%) showed intense uptake. In addition, of the 187 malignant nodules, 90 (48%) showed faint uptake, 71 (38%) showed moderate uptake, and 18 (10%) showed intense uptake. There was no significant difference in SUV<sub>max</sub> between the two nodule groups. Nineteen (19%) patients had a history of extra-thoracic cancer diagnosed within the last 5 years, and thirty-four patients (14%) had a family history of lung cancer.</p>
</sec>
<sec id="sec012">
<title>Receiver operating characteristic (ROC) curves for the four risk prediction models</title>
<p>The area under the ROC curve values (AUC, 95% CI) for each model were as follows (<xref ref-type="fig" rid="pone.0201242.g002">Fig 2</xref>): Mayo, 0.615 (0.528–0.701); VA, 0.604 (0.516–0.692); Brock, 0.682 (0.601–0.763); Herder, 0.557 (0.476–0.637). The predictive power of the Brock model was higher than that of the other models, and the Herder model had the lowest predictive power. The performance of the Herder model (AUC: 0.5567) was not statistically significantly different from that of the Mayo model (vs. Herder, p = 0.576) or the VA model (vs. Herder, p = 0.999), and there were no differences among the three models in the ability to determine the probability of malignancy in pulmonary nodules. However, compared with the Brock model, the Herder model showed a significantly lower ability to predict malignancy (adjusted p = 0.0132). The distribution of the probability of malignancy according to the four risk prediction models is shown in <xref ref-type="fig" rid="pone.0201242.g003">Fig 3</xref>.</p>
<fig id="pone.0201242.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Receiver operator characteristic curves for the four risk prediction models.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0201242.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Distribution of the probability of malignancy according to the four risk prediction models.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013">
<title>Decision analysis for the four risk prediction models</title>
<p>We also evaluated the malignancy probability thresholds informing clinical decision-making of the American College of Chest Physicians (ACCP) [<xref ref-type="bibr" rid="pone.0201242.ref016">16</xref>] and the British Thoracic Society (BTS) [<xref ref-type="bibr" rid="pone.0201242.ref017">17</xref>] (<xref ref-type="table" rid="pone.0201242.t002">Table 2</xref>): ACCP guidelines, observe (&lt; 5%), undetermined (5–65%), surgery (&gt; 65%); and BTS guidelines, observe (&lt; 10%), undetermined (10–70%), surgery (&gt;70%). As shown in <xref ref-type="table" rid="pone.0201242.t002">Table 2</xref>, the false-positive rate was highest with the Herder model (up to 6%) using both the ACCP and BTS thresholds, while the true negative rate with the Brock model was up to 4–5% using the ACCP and BTS thresholds. The decision curves for the four models also showed that the Brock model had the highest power for discriminating malignant nodules, while the Herder model showed the lowest discriminatory power (<xref ref-type="fig" rid="pone.0201242.g004">Fig 4</xref>).</p>
<fig id="pone.0201242.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Decision curve analysis for the four risk prediction models.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.g004" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0201242.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.t002</object-id>
<label>Table 2</label> <caption><title>Decision analysis using the ACCP and BTS thresholds in 242 confirmed nodules.</title></caption>
<alternatives>
<graphic id="pone.0201242.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify"/>
<th align="center">Brock</th>
<th align="center">Mayo</th>
<th align="center">VA</th>
<th align="center">Herder</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">ACCP</td>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
</tr>
<tr>
<td align="justify">    T.P</td>
<td align="center">3 (1)</td>
<td align="center">27 (11)</td>
<td align="center">36 (15)</td>
<td align="center">74 (30)</td>
</tr>
<tr>
<td align="justify">    T.N</td>
<td align="center">9 (4)</td>
<td align="center">10 (4)</td>
<td align="center">11 (5)</td>
<td align="center">0 (0)</td>
</tr>
<tr>
<td align="justify">    F.P</td>
<td align="center">0 (0)</td>
<td align="center">2 (1)</td>
<td align="center">5 (2)</td>
<td align="center">14 (6)</td>
</tr>
<tr>
<td align="justify">    F.N</td>
<td align="center">3 (1)</td>
<td align="center">8 (3)</td>
<td align="center">9 (4)</td>
<td align="center">0</td>
</tr>
<tr>
<td align="justify">    Undetermined</td>
<td align="center">227 (94)</td>
<td align="center">195 (81)</td>
<td align="center">181 (74)</td>
<td align="center">154 (64)</td>
</tr>
<tr>
<td align="justify">BTS</td>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
<td align="justify"/>
</tr>
<tr>
<td align="justify">    T.P</td>
<td align="center">2 (1)</td>
<td align="center">14 (6)</td>
<td align="center">33 (14)</td>
<td align="center">64 (26)</td>
</tr>
<tr>
<td align="justify">    T.N</td>
<td align="center">13 (5)</td>
<td align="center">17 (7)</td>
<td align="center">17 (7)</td>
<td align="center">5 (2)</td>
</tr>
<tr>
<td align="justify">    F.P</td>
<td align="center">0 (0)</td>
<td align="center">1 (1)</td>
<td align="center">5 (2)</td>
<td align="center">14 (6)</td>
</tr>
<tr>
<td align="justify">    F.N</td>
<td align="center">16 (7)</td>
<td align="center">29 (12)</td>
<td align="center">30 (12)</td>
<td align="center">9 (4)</td>
</tr>
<tr>
<td align="justify">    Undetermined</td>
<td align="center">211 (87)</td>
<td align="center">181 (74)</td>
<td align="center">157 (65)</td>
<td align="center">150 (62)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>The data are presented as numbers (%). ACCP, American College of Chest Physicians; BTS, British Thoracic Society; VA, Veterans Association; T.P, true positive; T.N, true negative; F.P, false-positive; F.N, false-negative.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Histopathological results of nodules</title>
<p>Histopathological results of the pulmonary nodules of the study patients are shown in <xref ref-type="table" rid="pone.0201242.t003">Table 3</xref>.Of the 55 confirmed benign nodules, granuloma was the most common type (n = 28, 51%), followed by fibrin (n = 10, 18%), organizing pneumonia (n = 6, 11%), hamartoma (n = 4, 7%), carcinoid (n = 3, 5%), and others (n = 4, 7%). Of the 28 granuloma nodules, 23 (82%) were tuberculosis granuloma, 3 (11%) were actinomycosis granuloma, and 2 (7%) were cryptococcosis granuloma. Of the 187 malignant nodules, 172 (92%) were adenocarcinoma, and the remaining 15 (8%) were squamous cell carcinoma.</p>
<table-wrap id="pone.0201242.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0201242.t003</object-id>
<label>Table 3</label> <caption><title>Histopathological results of pulmonary nodules.</title></caption>
<alternatives>
<graphic id="pone.0201242.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">Biopsy results</th>
<th align="center">Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">Benign</td>
<td align="center">(n = 55, 100%)</td>
</tr>
<tr>
<td align="justify">    Granuloma</td>
<td align="center">28 (51)</td>
</tr>
<tr>
<td align="justify">    Tuberculosis</td>
<td align="center">23/28</td>
</tr>
<tr>
<td align="justify">    Actinomycosis</td>
<td align="center">3/28</td>
</tr>
<tr>
<td align="justify">    Cryptococcosis</td>
<td align="center">2/28</td>
</tr>
<tr>
<td align="justify">    Fibrin</td>
<td align="center">10 (18)</td>
</tr>
<tr>
<td align="justify">    Organizing pneumonia</td>
<td align="center">6 (11)</td>
</tr>
<tr>
<td align="justify">    Hamartoma</td>
<td align="center">4 (7)</td>
</tr>
<tr>
<td align="justify">    Carcinoid</td>
<td align="center">3 (5)</td>
</tr>
<tr>
<td align="justify">    Others<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref></td>
<td align="center">4 (7)</td>
</tr>
<tr>
<td align="justify">Malignancy</td>
<td align="center">(n = 187, 100%)</td>
</tr>
<tr>
<td align="justify">    Adenocarcinoma</td>
<td align="center">172 (92)</td>
</tr>
<tr>
<td align="justify">    Squamous cell carcinoma</td>
<td align="center">15 (8)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p><sup>a</sup>Mucinous nodule, calcification nodule, lymphocyte aggravation, and sclerosing pneumocytoma were classified into the “Others” category.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec015" sec-type="conclusions">
<title>Discussion</title>
<p>Malignancy prediction models for pulmonary nodules should be applied with due consideration afforded to characteristics that may vary according to geographic region. The majority of malignancy prediction models were developed with Western populations in mind, and as such they are limited in their applicability to Asian populations. No universally applicable models for determining malignancy in pulmonary nodules are available, and the development of any such model should be executed with carefully and compared against the various extant risk models.</p>
<p>To our knowledge, this is the first study comparing the four models used to predict the probability of malignancy in the Korean population, especially in a tuberculosis-endemic area, to show how the various prediction models could be applied to local populations. Our results indicated that the Herder prediction model including the <sup>18</sup>FDG uptake value was not better than the other models in predicting malignant nodules, suggesting the limited utility of considering PET/CT in the malignancy prediction process in populations within endemic areas for benign inflammatory nodules, such as tuberculosis.</p>
<p>One explanation for our results is that PET/CT resulted in false-positive findings for benign conditions, including infection, inflammation (soft tissue trauma, collagen diseases), and granulomatous infections (sarcoidosis, tuberculosis) [<xref ref-type="bibr" rid="pone.0201242.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0201242.ref021">21</xref>]. In our study, there was no difference in SUV<sub>max</sub> on PET/CT between benign and malignant nodules. Moreover, half (24/48) of the benign nodules showed moderate or intense SUV values on PET/CT. Thus, before assessing malignancy risk using a prediction model, physicians should consider whether the prediction models are useful for their patient populations, because there is geographical variation in the prevalence of granulomatous disease [<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>]. Therefore, physicians should also be aware of the possibility of false-positive findings when applying malignancy prediction models including PET/CT findings.</p>
<p>The differences and similarities of the four prediction models are as follows. In all models, the risk of malignancy increased with age and nodule size. In the Mayo and VA models [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>], smoking history is included as an indicator to predict the malignancy of pulmonary nodules; in particular, the VA model includes the time of stopping smoking as a predictor [<xref ref-type="bibr" rid="pone.0201242.ref021">21</xref>]. The Mayo and Brock models [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>] include the location of nodules and spiculation as predictors of malignancy, but the VA [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>] model does not. In predicting the malignancy of pulmonary nodules, the VA and Brock models [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>–<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>] exclude cancer history, whereas the Mayo and Herder models [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0201242.ref011">11</xref>] include extrathoracic cancer more than 5 years prior. The Herder model is based on Mayo models including PET-CT characteristics [<xref ref-type="bibr" rid="pone.0201242.ref011">11</xref>]. Recent studies have reported that the Herder model incorporating FDG avidity has the highest accuracy in predicting the malignancy of pulmonary nodules, but this remains a subject of debate [<xref ref-type="bibr" rid="pone.0201242.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>].</p>
<p>In our study, the AUCs for all models was lower than those in previous studies. For example, although the AUC of the Brock model in our study (0.682; 95% CI: 0.6009–0.7630) was higher than that of the other models, it was lower than that in the original article by McWilliams et al. (AUC: 0.96; 95% CI: 0.93–0.98) [<xref ref-type="bibr" rid="pone.0201242.ref010">10</xref>]. In addition, the AUC of the other models was lower than that in the original article. For example, the AUC of the Mayo model in our study (AUC: 0.6145; 95% CI: 0.5283–0.7008) was lower than that reported in the original article by Swensen et al. (AUC: 0.833; 95% CI: 0.811–0.855) [<xref ref-type="bibr" rid="pone.0201242.ref008">8</xref>], and the AUC of the VA model (AUC: 0.6042; 95% CI: 0.5162–0.6922) was also lower than that reported in the original article by Michael et al. (AUC: 0.78; 95% CI: 0.73–0.83) [<xref ref-type="bibr" rid="pone.0201242.ref009">9</xref>]. The Herder score including the patients who underwent PET-CT had the lowest accuracy in predicting the malignancy of pulmonary nodules in our patients (AUC: 0.5567; 95% CI: 0.4763–0.6371), and showed a worse performance than that seen in the original report (AUC: 0.92; 95% CI: 0.87–0.97) [<xref ref-type="bibr" rid="pone.0201242.ref011">11</xref>]. Several factors could explain this result. First, the lower AUC values in our study might be due to differences in the methods used to enroll the patients. In the present study, patients with pulmonary nodules confirmed by biopsy were retrospectively identified, a strategy that was different from that used in other studies. Second, compared with western populations, the incidence of lung cancer is higher in non-smoking, middle-aged Asian women. Third, our results were determined according to the prevalence of different types of benign nodule. In our study, 77% of lesions were malignant nodules, and 33% were benign nodules; of the benign nodules, granulomas accounted for 51% of the cases and showed high uptake in PET-CT.</p>
<p>Our study population may reflect a degree of selection bias: as our hospital is a tertiary referral center and most patients were referred with suspected malignant nodules, the rate of malignancy among our study population was relatively higher than has been seen in previous studies. Moreover, we retrospectively analyzed patients with biopsy-proven nodules for whom surgery was strongly recommended, and therefore some patients whose nodules had not yet been surgically confirmed may have been excluded. Additionally, patients presenting with very small nodules may have undergone observation without further diagnostic evaluation, such as PET-CT. All of these factors may have had a bearing on our results.</p>
<p>As we also included nodules that had been confirmed by percutaneous needle aspiration, and not only by surgical resection, the median nodule size and incidence of malignancy were relatively high, possibly contributing further to selection bias. Finally, we used the categorized, semiquantitative SUV<sub>max</sub> values applied by Al-Ameri et al., which differs from the approach of Herder et al. [<xref ref-type="bibr" rid="pone.0201242.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0201242.ref011">11</xref>].</p>
<p>In conclusion, we retrospectively evaluated four models for predicting malignancy in patients with biopsy-proven lung nodules. The highest AUC value was seen for the Brock model, but there was no significant difference between this value and those of the Mayo model and VA models. However, the Brock model showed significantly higher accuracy for predicting malignancy than the Herder model, which included the <sup>18</sup>FDG uptake value, indicating the limited utility of PET/CT for predicting malignancy. When using prediction models to screen for the risk of malignancy of pulmonary nodules, physicians should consider the effects of regional differences, for example in terms of the prevalence of granulomatous disease.</p>
</sec>
<sec id="sec016">
<title>Supporting information</title>
<supplementary-material id="pone.0201242.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0201242.s001" xlink:type="simple">
<label>S1 Dataset</label>
<caption>
<title/>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0201242.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacobson</surname> <given-names>FL</given-names></name>. <article-title>Multidetector-row CT of lung cancer screening</article-title>. <source>Semin Roentgenol</source>. <year>2003</year>; <volume>38</volume>:<fpage>168</fpage>–<lpage>75</lpage>. <object-id pub-id-type="pmid">12854440</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perandini</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Soardi</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Larici</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Del Ciello</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rizzardi</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Solazzo</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Multicenter external validation of two malignancy risk prediction models in patients undergoing 18F-FDG-PET for solitary pulmonary nodule evaluation</article-title>. <source>Eur Radiol</source>. <year>2017</year>; <volume>27</volume>:<fpage>2042</fpage>–<lpage>6</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00330-016-4580-3" xlink:type="simple">https://doi.org/10.1007/s00330-016-4580-3</ext-link> <object-id pub-id-type="pmid">27631108</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aberle</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Berg</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Black</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Clapp</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Fagerstrom</surname> <given-names>RM</given-names></name>, <etal>et al</etal>. <article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening</article-title>. <source>N Engl J Med</source>. <year>2011</year>; <volume>365</volume>:<fpage>395</fpage>–<lpage>409</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1102873" xlink:type="simple">https://doi.org/10.1056/NEJMoa1102873</ext-link> <object-id pub-id-type="pmid">21714641</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Croswell</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Marcus</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Clapp</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Kramer</surname> <given-names>BS</given-names></name>. <article-title>Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial</article-title>. <source>Ann Intern Med</source>. <year>2010</year>; <volume>152</volume>:<fpage>505</fpage>–<lpage>12</lpage>, w176-80. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7326/0003-4819-152-8-201004200-00007" xlink:type="simple">https://doi.org/10.7326/0003-4819-152-8-201004200-00007</ext-link> <object-id pub-id-type="pmid">20404381</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bach</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Mirkin</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Oliver</surname> <given-names>TK</given-names></name>, <name name-style="western"><surname>Azzoli</surname> <given-names>CG</given-names></name>, <name name-style="western"><surname>Berry</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Brawley</surname> <given-names>OW</given-names></name>, <etal>et al</etal>. <article-title>Benefits and harms of CT screening for lung cancer: a systematic review</article-title>. <source>Jama</source>. <year>2012</year>; <volume>307</volume>:<fpage>2418</fpage>–<lpage>29</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2012.5521" xlink:type="simple">https://doi.org/10.1001/jama.2012.5521</ext-link> <object-id pub-id-type="pmid">22610500</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wood</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Eapen</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Ettinger</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Jackman</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Kazerooni</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Lung cancer screening</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2012</year>; <volume>10</volume>:<fpage>240</fpage>–<lpage>65</lpage>. <object-id pub-id-type="pmid">22308518</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Al-Ameri</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Malhotra</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Thygesen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Plant</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Vaidyanathan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Karthik</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Risk of malignancy in pulmonary nodules: A validation study of four prediction models</article-title>. <source>Lung Cancer</source>. <year>2015</year>; <volume>89</volume>:<fpage>27</fpage>–<lpage>30</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lungcan.2015.03.018" xlink:type="simple">https://doi.org/10.1016/j.lungcan.2015.03.018</ext-link> <object-id pub-id-type="pmid">25864782</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Swensen</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Silverstein</surname> <given-names>MD</given-names></name>, <name name-style="western"><surname>Ilstrup</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Schleck</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Edell</surname> <given-names>ES</given-names></name>. <article-title>The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules</article-title>. <source>Arch Intern Med</source>. <year>1997</year>; <volume>157</volume>:<fpage>849</fpage>–<lpage>55</lpage>. <object-id pub-id-type="pmid">9129544</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gould</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Ananth</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Barnett</surname> <given-names>PG</given-names></name>. <article-title>A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules</article-title>. <source>Chest</source>. <year>2007</year>; <volume>131</volume>:<fpage>383</fpage>–<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1378/chest.06-1261" xlink:type="simple">https://doi.org/10.1378/chest.06-1261</ext-link> <object-id pub-id-type="pmid">17296637</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McWilliams</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tammemagi</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Mayo</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Roberts</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Soghrati</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Probability of cancer in pulmonary nodules detected on first screening CT</article-title>. <source>N Engl J Med</source>. <year>2013</year>; <volume>369</volume>:<fpage>910</fpage>–<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1214726" xlink:type="simple">https://doi.org/10.1056/NEJMoa1214726</ext-link> <object-id pub-id-type="pmid">24004118</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Herder</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>van Tinteren</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Golding</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Kostense</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Comans</surname> <given-names>EF</given-names></name>, <name name-style="western"><surname>Smit</surname> <given-names>EF</given-names></name>, <etal>et al</etal>. <article-title>Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography</article-title>. <source>Chest</source>. <year>2005</year>; <volume>128</volume>:<fpage>2490</fpage>–<lpage>6</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1378/chest.128.4.2490" xlink:type="simple">https://doi.org/10.1378/chest.128.4.2490</ext-link> <object-id pub-id-type="pmid">16236914</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perandini</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Soardi</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Motton</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dallaserra</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Montemezzi</surname> <given-names>S</given-names></name>. <article-title>Limited value of logistic regression analysis in solid solitary pulmonary nodules characterization: a single-center experience on 288 consecutive cases</article-title>. <source>J Surg Oncol</source>. <year>2014</year>; <volume>110</volume>:<fpage>883</fpage>–<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jso.23730" xlink:type="simple">https://doi.org/10.1002/jso.23730</ext-link> <object-id pub-id-type="pmid">25088475</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Isbell</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Deppen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Putnam</surname> <given-names>JB</given-names> <suffix>Jr.</suffix></name>, <name name-style="western"><surname>Nesbitt</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Lambright</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Dawes</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation</article-title>. <source>Ann Thorac Surg</source>. <year>2011</year>; <volume>91</volume>:<fpage>227</fpage>–<lpage>33</lpage>; discussion 33. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.athoracsur.2010.08.054" xlink:type="simple">https://doi.org/10.1016/j.athoracsur.2010.08.054</ext-link> <object-id pub-id-type="pmid">21172518</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref014"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization. Global tuberculosis report. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/publications/global_report/en/" xlink:type="simple">http://www.who.int/tb/publications/global_report/en/</ext-link> (accessed 17.04.01). 2016</mixed-citation></ref>
<ref id="pone.0201242.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DeLong</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>DeLong</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Clarke-Pearson</surname> <given-names>DL</given-names></name>. <article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</article-title>. <source>Biometrics</source>. <year>1988</year>; <volume>44</volume>:<fpage>837</fpage>–<lpage>45</lpage>. <object-id pub-id-type="pmid">3203132</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gould</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Donington</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lynch</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Mazzone</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Midthun</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Naidich</surname> <given-names>DP</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines</article-title>. <source>Chest</source>. <year>2013</year>; <volume>143</volume>:<fpage>e93S</fpage>–<lpage>e120S</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1378/chest.12-2351" xlink:type="simple">https://doi.org/10.1378/chest.12-2351</ext-link> <object-id pub-id-type="pmid">23649456</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Callister</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Baldwin</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Akram</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Barnard</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cane</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Draffan</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>British Thoracic Society guidelines for the investigation and management of pulmonary nodules</article-title>. <source>Thorax</source>. <year>2015</year>; <volume>70</volume> <issue>Suppl 2</issue>:<fpage>ii1</fpage>–<lpage>ii54</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/thoraxjnl-2015-207168" xlink:type="simple">https://doi.org/10.1136/thoraxjnl-2015-207168</ext-link> <object-id pub-id-type="pmid">26082159</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patz</surname> <given-names>EF</given-names> <suffix>Jr.</suffix></name>, <name name-style="western"><surname>Lowe</surname> <given-names>VJ</given-names></name>, <name name-style="western"><surname>Hoffman</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Paine</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Burrowes</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Coleman</surname> <given-names>RE</given-names></name>, <etal>et al</etal>. <article-title>Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning</article-title>. <source>Radiology</source>. <year>1993</year>; <volume>188</volume>:<fpage>487</fpage>–<lpage>90</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1148/radiology.188.2.8327702" xlink:type="simple">https://doi.org/10.1148/radiology.188.2.8327702</ext-link> <object-id pub-id-type="pmid">8327702</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knight</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Delbeke</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Sandler</surname> <given-names>MP</given-names></name>. <article-title>Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy</article-title>. <source>Chest</source>. <year>1996</year>; <volume>109</volume>:<fpage>982</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">8635381</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gupta</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Maloof</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gunel</surname> <given-names>E</given-names></name>. <article-title>Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET</article-title>. <source>J Nucl Med</source>. <year>1996</year>; <volume>37</volume>:<fpage>943</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">8683316</object-id></mixed-citation></ref>
<ref id="pone.0201242.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>CQ</given-names></name>, <name name-style="western"><surname>Zuo</surname> <given-names>CT</given-names></name>, <name name-style="western"><surname>Le</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Guan</surname> <given-names>YH</given-names></name>, <etal>et al</etal>. <article-title>Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers</article-title>. <source>Chin Med J (Engl)</source>. <year>2009</year>; <volume>122</volume>:<fpage>1749</fpage>–<lpage>54</lpage>. <object-id pub-id-type="pmid">19781319</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>